Stevanato

STVN

Market cap $4.1B

The Fund rebounded and outperformed the Russell 2000 ® Growth Index in the fourth quarter. Boot Barn's revenues and earnings handily exceeded estimates, with greater transaction volumes and new store openings. Abivax reported strong clinical trial results for its obefazimod treatment to address ulcerative colitis in a longer lasting manner.

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will participate in the KeyBanc Capital Markets Virtual Healthcare Forum taking place on Tuesday, March 17 and Wednesday, March 18, 2026. The Company will present on Tuesday, March 17, at 9.45-10.20 a.m. (ET). A live webcast will be available o.

Stevanato Group is reiterated as a Buy, supported by strong Q4/FY25 results and robust long-term demand drivers. While the Engineering division continues to weigh on margins and reported less than €40m in Q4 sales, the pressure appears cyclical. With ~90% of capex directed toward HVS expansion, the segment has limited impact on the group's long-term fundamentals.

Stevanato Group S.p.A. (STVN) Q4 2025 Earnings Call Transcript

Stevanato Group (STVN) came out with quarterly earnings of $0.21 per share, beating the Zacks Consensus Estimate of $0.2 per share. This compares to earnings of $0.2 per share a year ago.

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, today announced its financial results for the fourth quarter and full year 2025. Fourth Quarter and Full Year 2025 Highlights (comparisons to prior-year periods) For the fourth quarter of 2025, revenue increased 5% (7% on a constant currency basis) to €346.5 million,.

PIOMBINO DESE, Italy--(BUSINESS WIRE)--Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries, announced today that it will issue financial results for the fourth quarter and fiscal year 2025 on Wednesday, March 4, 2026, at 6:30 a.m. (ET). Conference call and webcast: The Company will host a conference call and webcast at 8:30 a.m. (ET) on Wednesday, March 4, 2.

Class A shares of the Alger Small Cap Focus Fund outperformed the Russell 2000 Growth Index during the fourth quarter of 2025. Exact Sciences Corporation, Guardant Health, Inc., and Natera, Inc. were among the top contributors to performance. Nebius Group, uniQure N.V., and Stevanato Group were among the top detractors from performance.

Investors looking for stocks in the Medical - Drugs sector might want to consider either Stevanato Group (STVN) or Madrigal (MDGL). But which of these two stocks offers value investors a better bang for their buck right now?

Stevanato's biologics remain the core growth engine supported by a broad pipeline, resilient GLP-1 demand, vial recovery, and a favorable industry backdrop. While Engineering continues to weigh on margins in the short run, the weakness appears cyclical rather than structural, with optimization progressing and limited impact on group fundamentals. After a ~14% pullback, long-term earnings visibility remains strong, supporting higher 2026 profitability assumptions and a higher target price, leading us to maintain a constructive stance.